吸入性糖皮质激素与慢阻肺患者主要心血管事件的关系
在英格兰113 353例慢阻肺患者中,ICS处方与主要不良心血管事件(MACE)无显著关联(aHR 0.98,95%CI 0.95–1.02,p=0.41),但随访至第6年与心衰风险降低相关(平均aHR 0.91,95%CI 0.86–0.96,p<0.001)。新发ICS使用与急性冠脉综合征风险增加相关(HR 1.27,95%CI 1.09–1.47,p<0.001),但未持续。
要点
- ICS整体不降低MACE风险,但可能与心衰风险降低相关。
- 新发ICS使用初期急性冠脉综合征风险增加,但不持续。
- 含莫米松、倍氯米松、布地奈德或环索奈德的ICS与心衰降低相关。
核心结论
- ICS未降低MACE,但降低心衰风险,可能因减少误分类的慢阻肺急性加重。
- 新发ICS使用与急性冠脉综合征风险增加相关,但未持续。
- 三联疗法与MACE无关联,结果不受心血管病史影响。
研究设计与样本
- 队列研究,纳入英格兰慢阻肺患者113 353例,平均年龄67.9岁,53.3%男性。
- 采用Cox比例风险回归,必要时调整时间交互或使用倾向评分调整模型。
主要发现
- ICS处方与MACE无显著关联(aHR 0.98,95%CI 0.95–1.02,p=0.41)。
- ICS与随访至第6年心衰风险降低相关(平均aHR 0.91,95%CI 0.86–0.96,p<0.001)。
- 心衰降低由含莫米松、倍氯米松、布地奈德或环索奈德的ICS组驱动(HR 0.89,95%CI 0.84–0.94,p<0.001)。
- 新发ICS使用与急性冠脉综合征风险增加相关(HR 1.27,95%CI 1.09–1.47,p<0.001),但未持续。
- 三联疗法与MACE无关联,结果不因心血管病史而异。
关键数值与推荐
- MACE包括急性冠脉综合征、心衰、缺血性卒中或心血管特异性死亡。
- 暴露为随访前一年内任何ICS处方(对比任何长效支气管扩张剂)或三联疗法(对比联合长效支气管扩张剂)。
临床怎么用
- ICS不应用于降低慢阻肺患者MACE风险,但可能降低心衰风险。
- 新发ICS使用初期需关注急性冠脉综合征风险,但风险不持续。
- 含莫米松、倍氯米松、布地奈德或环索奈德的ICS与心衰降低相关。
局限性
- 心衰降低可能反映对误分类的慢阻肺急性加重的减少。
- 观察性设计可能受残余混杂影响。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Whether inhaled corticosteroids (ICSs) reduce major adverse cardiovascular events (MACEs) in people with chronic obstructive pulmonary disease (COPD) is debated. OBJECTIVES: To establish, within people with COPD, (1) whether ICS reduced MACE rates (acute coronary syndrome (ACS), heart failure (HF), ischaemic strokes or cardiovascular-specific death) compared with long-acting bronchodilators; and (2) whether drug class, incident usership or patient cardiovascular history influenced the ICS-MACE relationship. METHODS: We conducted a cohort study including patients with COPD in England, using Clinical Practice Research Datalink Aurum data, linked with Hospital Episode Statistics and Office of National Statistics death data, between 1 January 2010 and 31 December 2019. We implemented Cox proportional hazard regressions, adjusting for time interactions or using propensity score-adjusted models, as necessary. Our exposures included prescriptions of any ICS (vs any long-acting bronchodilators) and triple therapy (vs combination long-acting bronchodilators), determined during the year prior to follow-up. The outcomes of interest were MACE collectively and individual MACE subtypes. MEASUREMENTS AND MAIN RESULTS: Among 113 353 people with COPD (mean age 67.9 years old, 53.3% male), ICS prescription was not associated with MACE (adjusted HR (95% CI)=0.98 (0.95, 1.02), p=0.41) but was associated with reduced HF, specifically, until year 6 of follow-up (average adjusted HR (95% CI)=0.91 (0.86, 0.96), p<0.001). HF reduction was driven by the ICS group containing mometasone furoate, beclomethasone, budesonide or ciclesonide (HR (95% CI)=0.89 (0.84, 0.94), p<0.001). Incident ICS use was associated with increased ACS (HR (95% CI)=1.27 (1.09, 1.47), p<0.001) but was not sustained beyond incident use. There was no association between triple therapy and MACE. Results did not differ by cardiovascular history. CONCLUSIONS: ICS did not reduce MACE, except HF, likely by reducing misclassified COPD exacerbations.
引用
- Ioannides AE, Kallis C, Whittaker HR, et al. Inhaled corticosteroids and major cardiovascular events in people with chronic obstructive pulmonary disease. Thorax. 2025. PMID: 39721760. doi:10.1136/thorax-2024-222113
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。